13 Feb 2025 • A 15.7-year cohort study links steatotic liver disease (SLD) subtypes, sarcopenia, and fibrosis to increased mortality. While MASLD alone had a modest impact, its combination with sarcopenia doubled all-cause mortality risk (HR 2.19), and advanced fibrosis tripled it (HR 3.41).

Metabolic dysfunction and alcohol-associated liver disease (MetALD) and other SLD subtypes had even higher risks (HR 1.83 and 2.50, respectively), predominantly associated with cancer-related deaths.

These findings highlight the importance of early detection and management of MASLD, sarcopenia, and fibrosis to reduce mortality in affected patients.

Source: BMC Gastroenterology | Read Full Story